Infectious Diseases News and Research

RSS

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.

22 Jul 2010

AHF hosts 'Test & Treat: Getting to 10 Million on ARVs' satellite session

As both cost containment of care and services and treatment-as-prevention gain greater prominence in the global fight against HIV/AIDS during the Vienna AIDS Conference, AIDS Healthcare Foundation (AHF), which currently provides AIDS medical care to more than 139,000 individuals in 23 countries worldwide, will host a satellite session today, July 21st, titled "Test and Treat: Getting to 10 Million on ARVs" (IAC Mini Room #5 at 6:30pm) preceded by a press conference (5pm, Media Center, Room PCR #2).

22 Jul 2010

New era of scientific innovation to drive novel ways of treating, preventing HIV

The unwillingness of the global AIDS community to accept the status quo is fuelling a new era of scientific innovation to drive novel ways of treating and preventing HIV, organizers of the XVIII International AIDS Conference taking place in Vienna, Austria said today. And, with millions of lives dependent on expanding access to antiretroviral treatment to all those clinically in need, researchers and clinicians are partnering in new ways to find the most effective and efficient methods to deliver treatment and strengthen health systems.

22 Jul 2010

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Study links application of disinfectants in recreational pools to adverse health outcomes

Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.

22 Jul 2010

Study marks significant milestone for microbicide research field, HIV prevention

Today we congratulate the Centre for the AIDS Programme of Research in South Africa and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

22 Jul 2010

Experts outline three elements necessary for ending HIV/AIDS pandemic

According to a new editorial, the world can control and ultimately end the HIV/AIDS pandemic through a three-pronged strategy

22 Jul 2010

AIDS 2010 studies, releases: PMTCT, treating children, male circumcision; National prevention programs; IDUs

"In parts of Africa, only about half of babies born to mothers with HIV receive the HIV prevention drug nevirapine," according to a study published Wednesday, HealthDay News/U.S. News & World Report reports.

22 Jul 2010

CFAR receives a five-year renewal grant to continue AIDS research

The Case Western Reserve University/University Hospitals Case Medical Center Center for AIDS Research announced today it has received a five-year renewal grant from the National Institutes of Health for $9 million. The CFAR provides clinical and technological support to researchers working on HIV-related projects at Case Western Reserve, University Hospital Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, and several international sites.

22 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

The call for human rights as a fundamental component of efforts to prevent new infections and provide treatment for people living with HIV pervaded the XVIII International AIDS Conference today as delegates and local residents prepared for the HIV and Human Rights March through the streets of Vienna this evening. Conference participants are giving voice to the conference theme of Rights Here, Right Now through a number of plenary presentations, sessions, and Global Village and Youth Programme activities.

21 Jul 2010

AMP particpates at FDA's public meeting on oversight of laboratory developed tests

The Association for Molecular Pathology participated in the Food and Drug Administration Center for Devices and Radiological Health public meeting on the oversight of laboratory developed tests. Dr. Karen Mann, President of AMP, served on the second panel of the meeting titled, Clinical Laboratory Challenges. Additionally, Dr. Elaine Lyon, Chair of the AMP Professional Relations Committee, presented public comments. "AMP believes that LDTs are an essential and central component of medical practice," said Dr. Lyon, "Without LDTs, the practice of medicine that we know today would be severely reduced in scope."

21 Jul 2010

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

A microbicide gel containing Gilead's HIV drug tenofovir used by women before and after sex has been shown to reduce their risk of HIV infection by nearly 40%, according to a study unveiled at the International AIDS Conference-AIDS 2010, Reuters reports

21 Jul 2010

Natural, needle-free vaccination against malaria

If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections. This discovery was made by the team headed by Dr. Steffen Borrmann from the Department of Infectious Diseases at Heidelberg University Hospital in cooperation with Dr. Kai Matuschewski of the Max Planck Institute for Infection Biology in Berlin. The scientists think that safe and affordable prophylaxis with antibiotics in residents of areas with high malaria transmission has the potential to be used as a natural "needle-free" vaccination against malaria.

21 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

In the ongoing battle to prevent mother-to-child transmission of human immunodeficiency virus (HIV), not all weapons are being used: Only about half of HIV-exposed infants in some African countries received a minimal dose of the prevention drug nevirapine, say researchers at the University of Alabama at Birmingham.

20 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

Re-framing climate change issue helps people better understand climate-related problem: Research

Framing climate change as a public health problem seems to make the issue more relevant, significant and understandable to members of the public-even some who don't generally believe climate change is happening, according to preliminary research by George Mason University's Center for Climate Change Communication.

20 Jul 2010

Scientists find major shortcomings in assessing CVD risk in HIV patients

At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus, two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease risk in people with HIV with significant implications for improving medical care.

20 Jul 2010

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

"Treating HIV patients with cocktails of AIDS drugs helps to stop them spreading the infection further and more than halved the number of new HIV diagnoses in a study in Canada, scientists said on Sunday," Reuters reports.

20 Jul 2010

Infectious Diseases News and Research

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

AHF hosts 'Test & Treat: Getting to 10 Million on ARVs' satellite session

New era of scientific innovation to drive novel ways of treating, preventing HIV

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Study links application of disinfectants in recreational pools to adverse health outcomes

Study marks significant milestone for microbicide research field, HIV prevention

Experts outline three elements necessary for ending HIV/AIDS pandemic

AIDS 2010 studies, releases: PMTCT, treating children, male circumcision; National prevention programs; IDUs

CFAR receives a five-year renewal grant to continue AIDS research

New insights on early pathogenic events, strategies for preventing HIV infection

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

AMP particpates at FDA's public meeting on oversight of laboratory developed tests

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

Natural, needle-free vaccination against malaria

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

NanoViricides presents study results of nanoviricides anti-Ebola agents

Re-framing climate change issue helps people better understand climate-related problem: Research

Scientists find major shortcomings in assessing CVD risk in HIV patients

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News